BWXT to produce medical radioisotope germanium-68

4 November 2019

Canada’s BWX Technologies (BWXT) announced on 30 October that it plans to produce germanium-68 (Ge-68) with a focus on addressing growing global demand for the product.

BWXT’s isotope technologies group has developed proprietary manufacturing technology to produce high purity Ge-68. It is in the process of scaling up its capacity to move into full production in 2020 to address growing global customer demands.

Ge-68 will be produced using cyclotrons at BWXT’s Vancouver facility located at the TRIUMF particle accelerator centre. BWXT’s Ge-68 product will be used in gallium-68 (Ga-68) generators, a source of the diagnostic radioisotope Ga-68 used in positron emission tomography (PET). Diagnostic applications for Ga-68 include prostate cancer and neuroendocrine tumours. Several other therapeutic and Ga-68 imaging agents are in various stages of development and clinical trials that are expected to result in a further increase in demand for Ga-68.
 
Ge-68 is the third new medical radioisotope development project underway at BWXT. In 2018, BWXT announced that it had developed an innovative and unique process to manufacture molybdenum-99 (Mo-99). In late September, the company announced the availability of its generic version of Indium In-111 Oxyquinoline Solution. BWXT also markets four other radiochemical solutions (Indium-111, Iodine-123, Palladium-103 and Strontium-82).

“BWXT is in an excellent position to be able to respond to the market’s growing demand for this critical radioisotope,” said BWXT president and CEO Rex D Geveden. “We acquired the medical isotope business just over a year ago, and we are very pleased with this business and its growing portfolio of products.”



Privacy Policy
We have updated our privacy policy. In the latest update it explains what cookies are and how we use them on our site. To learn more about cookies and their benefits, please view our privacy policy. Please be aware that parts of this site will not function correctly if you disable cookies. By continuing to use this site, you consent to our use of cookies in accordance with our privacy policy unless you have disabled them.